As global markets continue to navigate the complexities of rising inflation and shifting trade policies, U.S. stock indexes have climbed toward record highs, with growth stocks leading the charge. In this environment, companies with high insider ownership can offer unique insights into potential future performance, as insiders often have a vested interest in the company's success and may align their strategies accordingly.
Name | Insider Ownership | Earnings Growth |
Seojin SystemLtd (KOSDAQ:A178320) | 32.1% | 39.9% |
Clinuvel Pharmaceuticals (ASX:CUV) | 10.4% | 26.2% |
SKS Technologies Group (ASX:SKS) | 29.7% | 24.8% |
Pricol (NSEI:PRICOLLTD) | 25.4% | 25.2% |
Laopu Gold (SEHK:6181) | 36.4% | 39.1% |
Pharma Mar (BME:PHM) | 11.9% | 45.4% |
HANA Micron (KOSDAQ:A067310) | 18.3% | 119.4% |
Plenti Group (ASX:PLT) | 12.7% | 120.1% |
Fulin Precision (SZSE:300432) | 13.6% | 71% |
Findi (ASX:FND) | 35.8% | 133.7% |
Click here to see the full list of 1458 stocks from our Fast Growing Companies With High Insider Ownership screener.
We'll examine a selection from our screener results.
Simply Wall St Growth Rating: ★★★★★★
Overview: Pharma Mar, S.A. is a biopharmaceutical company focused on the research, development, production, and commercialization of bio-active principles for oncology across various countries including Spain, Italy, Germany, Ireland, France, the rest of the EU and the United States; it has a market cap of approximately €1.71 billion.
Operations: The company generates revenue primarily from its oncology segment, which amounts to €154.75 million.
Insider Ownership: 11.9%
Revenue Growth Forecast: 23.8% p.a.
Pharma Mar shows potential as a growth company with high insider ownership. Its earnings are forecast to grow significantly at 45.4% annually, outpacing the Spanish market's 7.3%. Revenue is also expected to rise by 23.8% per year, exceeding the market average of 5.2%. Despite a volatile share price and reduced profit margins from last year, it trades at 30.3% below its estimated fair value, indicating possible undervaluation amidst strong growth prospects.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: BICO Group AB (publ) is a bioconvergence company with operations in North America, Europe, Asia, and internationally, and has a market cap of SEK2.93 billion.
Operations: BICO Group generates revenue from its operations across North America, Europe, Asia, and other international markets.
Insider Ownership: 25.2%
Revenue Growth Forecast: 13.2% p.a.
BICO Group demonstrates potential with high insider ownership, despite recent volatility. The company's revenue is forecast to grow at 13.2% annually, surpassing the Swedish market average of 1%. While currently unprofitable, BICO is expected to achieve profitability within three years, reflecting above-average market growth. Recent earnings showed a significant turnaround with a net income of SEK 346.8 million in Q4 2024 compared to a loss the previous year, highlighting positive momentum amidst its competitive valuation.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Shenzhen SEICHI Technologies Co., Ltd. specializes in the R&D, production, and sale of new display device testing equipment in China with a market cap of CN¥7.69 billion.
Operations: Revenue Segments (in millions of CN¥):
Insider Ownership: 18.6%
Revenue Growth Forecast: 29.1% p.a.
Shenzhen SEICHI Technologies shows promise with significant insider ownership, although its share price has been volatile recently. The company’s earnings are projected to grow at a substantial 42.62% annually over the next three years, outpacing the Chinese market average of 25%. Revenue is also expected to rise by 29.1% per year, exceeding market growth rates. However, profit margins have declined from last year and return on equity remains low at a forecasted 11.5%.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include BME:PHM OM:BICO and SHSE:688627.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。